Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-467-4577
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions
What is Allena Pharmaceuticals' stock symbol?
Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."
How were Allena Pharmaceuticals' earnings last quarter?
Allena Pharmaceuticals Inc (NASDAQ:ALNA) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.01. View Allena Pharmaceuticals' Earnings History.
When is Allena Pharmaceuticals' next earnings date?
What price target have analysts set for ALNA?
6 brokerages have issued 12 month price targets for Allena Pharmaceuticals' stock. Their predictions range from $20.00 to $36.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $26.1667 in the next twelve months. This suggests a possible upside of 585.0% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.
What is the consensus analysts' recommendation for Allena Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.
Has Allena Pharmaceuticals been receiving favorable news coverage?
News stories about ALNA stock have been trending negative on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Allena Pharmaceuticals.
Are investors shorting Allena Pharmaceuticals?
Allena Pharmaceuticals saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 86,800 shares, a drop of 39.8% from the June 30th total of 144,300 shares. Based on an average daily trading volume, of 137,500 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the company's shares are sold short. View Allena Pharmaceuticals' Current Options Chain.
Who are some of Allena Pharmaceuticals' key competitors?
Some companies that are related to Allena Pharmaceuticals include Agenus (AGEN), Tcr2 Therapeutics (TCRR), Prevail Therapeutics (PRVL), Gritstone Oncology (GRTS), AVITA MED LTD/S (AVMXY), Replimune Group (REPL), CASI Pharmaceuticals (CASI), PDL BioPharma (PDLI), BioCryst Pharmaceuticals (BCRX), Harpoon Therapeutics (HARP), Scholar Rock (SRRK), La Jolla Pharmaceutical (LJPC), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG) and ADMA Biologics (ADMA).
What other stocks do shareholders of Allena Pharmaceuticals own?
Who are Allena Pharmaceuticals' key executives?
Allena Pharmaceuticals' management team includes the folowing people:
- Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 66)
- Dr. Louis Brenner, Pres, CEO & Director (Age 49)
- Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 59)
- Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 54)
- Mr. Hugh Wight, Sr. VP of Technical Operations
When did Allena Pharmaceuticals IPO?
(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Allena Pharmaceuticals' major shareholders?
Allena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Morgan Stanley (7.43%), Vanguard Group Inc. (2.00%), BlackRock Inc. (0.49%), Northern Trust Corp (0.48%), Paloma Partners Management Co (0.22%) and JPMorgan Chase & Co. (0.23%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals.
Which institutional investors are selling Allena Pharmaceuticals stock?
ALNA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Vanguard Group Inc., Morgan Stanley, Wells Fargo & Company MN, Northern Trust Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Allena Pharmaceuticals.
Which institutional investors are buying Allena Pharmaceuticals stock?
ALNA stock was bought by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, Susquehanna International Group LLP, Jane Street Group LLC, Wedbush Securities Inc. and Jacobs Levy Equity Management Inc.. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.
How do I buy shares of Allena Pharmaceuticals?
Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allena Pharmaceuticals' stock price today?
One share of ALNA stock can currently be purchased for approximately $3.82.
How big of a company is Allena Pharmaceuticals?
Allena Pharmaceuticals has a market capitalization of $89.66 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe.View Additional Information About Allena Pharmaceuticals.
What is Allena Pharmaceuticals' official website?
How can I contact Allena Pharmaceuticals?
Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.
MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
